HDII (Hypertension Diagnostics) Altman Z2-Score: -90.18 (As of Jun. 25, 2026)


What is Hypertension Diagnostics Altman Z2-Score?

Hypertension Diagnostics HDII -99.00% Altman Z2-Score is -90.18 as of Jun. 25, 2026.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Hypertension Diagnostics has a Altman Z2-Score of -90.18, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Hypertension Diagnostics's Altman Z2-Score or its related term are showing as below:


Hypertension Diagnostics  (OTCPK:HDII) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Hypertension Diagnostics Altman Z2-Score Related Terms


Hypertension Diagnostics Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Hypertension Diagnostics's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hypertension Diagnostics Altman Z2-Score Chart

Hypertension Diagnostics Annual Data
Trend Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Dec16 Dec17 Dec18
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hypertension Diagnostics Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Dec16 Dec17 Dec18 Mar19 Jun19 Sep19
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HDII vs ESTRF, OCLN, PTOI: Altman Z2-Score Comparison

For the Shell Companies subindustry, Hypertension Diagnostics's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hypertension Diagnostics Altman Z2-Score vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Hypertension Diagnostics's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Hypertension Diagnostics's Altman Z2-Score falls into.



Hypertension Diagnostics Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Hypertension Diagnostics's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*-0.4992+3.26*-26.4038+6.72*0+1.05*-0.7891
=-90.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2019:
Total Assets was $1.28 Mil.
Total Current Assets was $0.71 Mil.
Total Current Liabilities was $1.34 Mil.
Retained Earnings was $-33.74 Mil.
Pre-Tax Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Liabilities was $6.03 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.706 - 1.344)/1.278
=-0.4992

X2=Retained Earnings/Total Assets
=-33.744/1.278
=-26.4038

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(0 - 0)/1.278
=0

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(-4.752 - 0.006)/6.03
=-0.7891

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Hypertension Diagnostics has a Altman Z2-Score of -90.18 indicating it is in Distress Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of -90.18 mean?
Hypertension Diagnostics (HDII) has a Altman Z2-Score of -90.18 as of Jun. 25, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Hypertension Diagnostics and its competitors.
Is Hypertension Diagnostics' Altman Z2-Score too high?
Hypertension Diagnostics' current Altman Z2-Score is -90.18.
How does Hypertension Diagnostics' Altman Z2-Score compare to ESTRF and OCLN?
Hypertension Diagnostics' Altman Z2-Score of -90.18 can be compared against companies in the Diversified Financial Services industry. The industry median Altman Z2-Score is 10.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Diversified Financial Services company?
The median Altman Z2-Score among Diversified Financial Services companies is 10.95, based on 422 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Hypertension Diagnostics and its competitors. For the Diversified Financial Services industry, the median Altman Z2-Score is 10.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hypertension Diagnostics's current Altman Z2-Score is -90.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypertension Diagnostics stock overvalued right now?
Hypertension Diagnostics (HDII) has a current Altman Z2-Score of -90.18. The current Altman Z2-Score is -90.18. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Hypertension Diagnostics (HDII), the current Altman Z2-Score is -90.18 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hypertension Diagnostics Business Description

Address 550 Highway 7 Unit 316, Ontario, ON, CAN, L4B324
Hypertension Diagnostics Inc is a shell company.